Table 2 Clinical outcomes during 1 year of trastuzumab treatment
Clinical outcomes | Total group (N = 135), (%) | Early-stage (N = 113), (%) | Advanced-stage (N = 22), (%) |
|---|---|---|---|
Cardiac events | |||
 Trastuzumab-induced cardiotoxicity | |||
  Solely LVEF < 45% | 1 (1) | 0 | 1 (5) |
  Solely absolute LVEF decline > 10% from baseline | 29 (21) | 26 (23) | 3 (14) |
  LVEF < 45% and absolute decline > 10% from baseline | 15 (11) | 12 (11) | 3 (14) |
  Totala | 45 (33) | 38 (34) | 7 (32) |
  Atrial fibrillation | 0 | 0 | 0 |
  Myocardial ischemia | 0 | 0 | 0 |
  Other cardiac events | 0 | 0 | 0 |
  Diastolic dysfunction grade 3 or 4 | 2 (2) | 1 (1) | 1 (5) |
Postponement of trastuzumab | |||
 Temporarily | 6 (4) | 6 (5) | 0 |
 Permanent | 14 (10) | 12 (11) | 2 (9) |
Death | |||
 Progression disease | 4 (3) | 2 (2) | 2 (9) |